Catalent Pharma Solutions, today announced that Dr. David Fulper, Director, Technology Support, will be presenting at the upcoming Cannabis-Based Therapies Summit, to be held at the Hyatt Centric Fisherman's Wharf Hotel, San Francisco, on Nov. 30 – Dec. 1, 2016.
Somerset, N.J. – November 29, 2016 — Catalent Pharma Solutions, the leading global provider of advanced delivery technologies and development solutions for drugs, biologics and consumer health products, today announced that Dr. David Fulper, Director, Technology Support, will be presenting at the upcoming Cannabis-Based Therapies Summit, to be held at the Hyatt Centric Fisherman’s Wharf Hotel, San Francisco, on Nov. 30 – Dec. 1, 2016.
Dr. Fulper’s presentation, on Wednesday, Nov. 30 at 4 p.m., is entitled “Leveraging Technology for the Development & Commercialization of Cannabis Drugs,” and will discuss the unique challenges that the drug properties of cannabis compounds pose to formulation scientists, as well as the selection of suitable process technologies. The presentation will explore the current drug delivery platforms available to reliably deliver cannabis molecules to the body, as well as looking towards the next generation of cannabis drug products, and how emerging technologies can improve both therapeutic effectiveness and patient compliance.
Dr. David Fulper is Director of Technology Support, at Catalent Pharma Solutions in St. Petersburg, Florida. He joined R.P. Scherer, which later became Catalent, in 1997 and has held various positions in R&D and operations. Prior to joining Catalent he worked for Schering Plough and was Director of Liquid Filled Capsules at Patheon Pharmaceuticals. He received his master’s and doctorate in pharmaceutics from the University of Mississippi.
For more information on the Conference, visit: http://www.cbinet.com/conference/pc16091 and to arrange a meeting with Dr. Fulper at the event, contact Richard Kerns at NEPR – richard@nepr.eu
About Catalent
Catalent is the leading global provider of advanced delivery technologies and development solutions for drugs, biologics and consumer health products. With over 80 years serving the industry, Catalent has proven expertise in bringing more customer products to market faster, enhancing product performance and ensuring reliable clinical and commercial product supply. Catalent employs approximately 9,500 people, including over 1,400 scientists, at more than 30 facilities across five continents, and in fiscal 2016 generated $1.85 billion in annual revenue. Catalent is headquartered in Somerset, New Jersey. For more information, visit www.catalent.com